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Gingko biloba has been used for hundreds of years to treat various disorders such as asthma, vertigo, fatigue and, tinnitus
or circulatory problems. Two of the main extracts are EGb761 and LI 1370. Most pharmacological, toxicological and
clinical studies have focused on the neuroprotective value of these two main extracts. Neuroprotection is a rapidly
expanding area of research. This area is of particular interest due to the fact that it represents a new avenue of therapy for
a frustrating disease that may progress despite optimal treatment. One such disease is glaucoma.Glaucoma leads to the
loss of retinal ganglion cells and their axons but also to tissue remodelling which involves both the optic nerve head and
the retina. In the retina the astrocytes get activated. In addition, the optic nerve gets thinner and the cells of the lateral
geniculate ganglion disappear partially. On average, ocular blood flow (OBF) is reduced in glaucoma patients in various
tissues of the eye. Increased intraocular pressure (IOP) is a major risk factor for glaucomatous damage. Nevertheless,
there is little doubt that other risk factors besides IOP are involved. One such risk factor is a primary vascular dysregulation
(PVD) occurring in patients with a disturbed autoregulation, another risk factor is oxidative stress.
Gingko biloba has existed for over 250 million years and
is indigenous to Korea, Japan, and China, but can be found
worldwide. It may grow to 40 m, and live for over 1,000 years.
The extracts of the gingko biloba leaves have been used for
hundreds of years to treat various disorders such as asthma,
vertigo, fatigue, and tinnitus or circulatory problems [1-3].
These  extracts  consist  mainly  of  flavonoids  and
terpenoids. Two of the main extracts are EGb761 and LI 1370.
Most  pharmacological,  toxicological,  and  clinical  studies
have focused on the neuroprotective value of these two main
extracts [4-6].
Neuroprotection is a rapidly expanding area of research.
This  area  is  of  particular  interest  due  to  the  fact  that  it
represents a new avenue of therapy for a frustrating disease
that may progress despite optimal treatment [7]. One such
disease is glaucoma.
Glaucoma leads to the loss of retinal ganglion cells and
their axons but also to tissue remodeling which involves both
the optic nerve head and the retina. In the retina, the astrocytes
get activated. In addition, the optic nerve gets thinner and the
cells of the lateral geniculate ganglion disappear partially [8].
On average, blood flow is reduced in glaucoma patients in
various  tissues  of  the  eye.  Blood  flow  reduction  is  more
pronounced in normal tension glaucoma (NTG) than in high
tension glaucoma (HTG) and comparatively, more in patients
with progressive types of glaucoma than those with stable
forms of glaucoma [9].
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Increased intraocular pressure (IOP) is a major risk factor
for glaucomatous damage and it is well established that an IOP
reduction improves, on average, the prognosis of all types of
glaucoma. Nevertheless, there is little doubt that other risk
factors besides IOP are involved so that even an ideal IOP
does not stop progression in all patients [10]. The objective of
this review is to provide a scientific opinion on the indications
for Ginkgo biloba as an adjuvant therapy for normal tension
glaucoma patients and for high tension glaucoma patients
progressing despite a normalized IOP.
PHARMACOLOGICAL PROPERTIES OF GINKGO
BILOBA EXTRACT
Antioxidative  effects:  Ginkgo  contains  many  different
flavonoids,  including  polyphenolic  flavanoids  which  have
been proven to exert antioxidative properties by delivering
electrons to free radicals [11].
Many compounds, such as e.g., vitamins E and C also
have antioxidative properties. The particularity of Ginkgo
biloba extract is that unlike vitamins E and C, the polyphenolic
flavanoids are able to act at the mitochondrial level.
In an in vitro study, PC12 cells were used to examine the
protective features of EGb761 on mitochondria stressed with
hydrogen peroxide and antimycin, an inhibitor of complex III
[12] (Figure 1). In addition, the efficacy of EGb761 in the
Abeta-induced  3-(4,5  dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reduction in PC12 cells
was examined. The authors of the study also examined the
effects of EGb761 on reactive oxygen species (ROS) levels
and ROS-induced apoptosis in lymphocytes from aged mice
after  in  vivo  administration.  EGb761  was  able  to  protect
mitochondria from the attack of hydrogen peroxide, antimycin
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390and Abeta. Furthermore, EGb761 reduced ROS levels and
ROS-induced  apoptosis  in  lymphocytes  from  aged  mice
treated orally with EGb761 for 2 weeks. These data support
neuroprotective  properties  of  EGb761,  such  as  protection
against Abeta-toxicity and antiapoptotic properties which are
probably  due  to  Ginkgo’s  antioxidative  effect  at  the
mitochondrial level.
Stabilization of the mitochondria: The mitochondria play a
major role in several diseases, particularly neurodegenerative
diseases, including glaucoma.
Indeed  Abu-Amero  et  al.  [13]  revealed  several
mitochondrial abnormalities in patients with glaucoma. They
examined 27 patients with definite chronic glaucoma patients
and  analyzed  the  following  parameters:  a)  the  myocilin
(MYOC) and the optineurin (OPTN) genes were sequenced,
b) the entire mitochondrial DNA (mtDNA) coding region was
sequenced, c) relative mtDNA content was investigated, and
d) the mitochondrial respiratory function was assessed. The
authors of the study found only three benign polymorphisms,
which were identified in MYOC and OPTN in patients with
primary  open-angle  glaucoma  (POAG)  and  in  control
subjects.  Conversely,  27  different  novel  non-synonymous
mtDNA changes were found, only in patients with POAG (not
control subjects), 22 of which (found in 14 patients) were
potentially  pathogenic.  mtDNA  content  was  relatively
increased  in  17  patients  with  POAG  compared  with  age-
matched control subjects, also implying a possible response
to oxidative stress. Mean mitochondrial respiratory activity
was decreased significantly by 21% in patients with glaucoma
compared  with  control  subjects.  These  results  reveal  a
spectrum  of  mitochondrial  abnormalities  in  patients  with
glaucoma and may open up new experimental and therapeutic
opportunities for glaucoma.
Besides, oxidative damage in mitochondria is particularly
relevant  for  the  following  reasons:  a)  the  mitochondria
themselves are major sources of free radicals, b) mitochondria
have a reduced DNA repair capacity, c) an oxidative damage
leads to reduced membrane potential and thereby a reduced
ATP-production; this shifts the cell in a low energy state and
makes the cell more vulnerable to other damaging factors, d)
if the damage of the mitochondria exceeds a certain level,
cytochrome C is released and this molecule then starts a chain
reaction leading to apoptosis.
Ginkgo has been proven to act at the mitochondrial level,
by  stabilizing  the  inner  membrane  and  increasing  the
membrane  potential,  restoring  the  respiratory  chain  and
increasing  ATP-production.  Abdel-Kader  et  al.  [14]  used
PC12 cells, dissociated mice brain cells, as well as isolated
mitochondria  to  investigate  the  effects  of  EGb761  on
mitochondrial  functions.  They  mimicked  mitochondrial
abnormalities  during  aging  by  using  external  factors
(nitrosative  stress,  serum  deprivation  and  complexes
inhibitors) which are altering mitochondrial processes, such
as  energy  metabolism.  As  markers  for  the  function  of
Figure 1. Stabilization of mitochondrial
membrane  potential.  A:  In  vitro
treatment  with  EGb  761  after  H2O2
insult  improves  the  reduction  of
mitochondrial  membrane  potential  in
dissociated  mouse  brain  cells.  Brain
cells were damaged with H2O2 (5 mM)
for 1 h; then EGb 761 was added for 6
h. B: In vivo treatment with EGb 761
improves the decrease of ATP levels in
dissociated brain cells. Treated animals
received 100 mg/kg EGb 761 p.o. once
daily for 2 weeks. Control animals were
treated  with  placebo  (0.9%  NaCl
solution).  ATP  levels  were  measured
after  a  2  h  incubation  of  dissociated
mouse brain cells with 2mM H2O2. C:
In  vivo  treatment  with  EGb761
improves  mitochondrial  membrane
potential of isolated mitochondria after
H2O2 insult. Treated animals received
100 mg/kg EGb 761 p.o. once daily for
2 weeks. Control animal were treated
with  placebo  (0.9%  NaCl  solution).
Mitochondrial membrane potential was
measured after a 2 h incubation with 2
mM H2O2. Reproduced with permission
from Eckert et al. [12].
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391mitochondria,  ATP  levels  and  mitochondrial  membrane
potential were measured. EGb761 alleviated mitochondrial
functions in vitro at concentrations as low as 0.01 mg/ml.
Treating  two  different  age  groups  of  mice  with  EGb761
(100  mg/kg  bodyweight  for  14  days)  showed  beneficial
effects  on  complexes  I,  IV,  and  V  of  the  mitochondrial
respiratory chain and against nitrosative stress. Interestingly,
these effects were only observed in the aged mice group,
proving higher efficacy of Ginkgo during aging. The single
components of Ginkgo extract showed a protective effect in
both cell models of the mitochondrial membrane potential as
well. This indicates that the components of Ginkgo act in a
complementary manner to enable mitochondria stabilization.
Anti-inflammatory  effects:  Many  diseases,  including
neurodegenerative  diseases,  have  a  certain  inflammatory
component. These are normally not acute inflammations, but
rather low-grade inflammations affecting certain cells, like for
e.g., the glial cells in the brain. When these cells are activated,
they produce inflammatory molecules such as TNFα, NOS-2,
COX-2, etc.
Ginkgo extract has been shown to reduce the activation
of cells (e.g., when activated through ischemia/reperfusion);
under treatment with EGb761, NOS-2 is less upregulated and
thereby less NO is produced. NO is a benign molecule, that
has several important physiologic functions. However, if NO
production is increased in areas with oxidative stress, NO-
fuses with O2-, thus releasing ONOO-, a highly cell damaging
molecule [10].
In their study, Varga et al. [15] could demonstrate the dual
effect of EGb761: it decreases the production of O2- and
reduces the production of NO.
Rheological effects: Rheological alterations occur in several
clinical  conditions.  These  alterations  affect  the
macrocirculation to a lesser extent, while it has a significant
effect on microcirculation. The relevance of the rheological
alteration in ocular disease has been investigated by Sofi F et
al.  [16].  The  authors  of  this  article  studied  the
hemorheological  profile  in  180  patients  with  retinal  vein
occlusion (RVO) and in 180 healthy subjects comparable for
age  and  gender.  Their  data  indicate  that  an  alteration  of
hemorheological parameters may modulate the susceptibility
to the RVO. Ginkgo promotes erythrocytes deformability,
decreases  fibrinogen  levels,  improves  blood  viscosity  and
viscoelasticity.
Indeed Huang et al. [17] demonstrated the improvement
in abnormal hemorheological parameters after ingestion of
Ginkgo  biloba  extract.  Hemorheological  parameters  were
measured before and 3 months after EGb761 oral ingestion in
25  type  2  diabetic  patients  with  retinopathy.  After  taking
EGb761  orally  for  3  months,  the  blood  viscosity  was
significantly  reduced,  viscoelasticity  was  significantly
reduced  in  diabetic  patients,  the  level  of  erythrocyte
malondialdehyde  (MDA)  was  reduced  by  30%,  and  the
deformability of erythrocyte was increased by 20%. Lastly,
retinal capillary blood flow rate increased significantly. The
authors  of  the  study  conclude  that  oral  administration  of
EGb761  enables  to  improve  hemorheological  parameters,
which in turn may facilitate blood perfusion.
Antithrombotic  properties:  Ginkgo  extract  has  an
antithrombotic  effect.  However,  the  actual  data  do  not
corroborate the hypothesis Ginkgo extract may significantly
increase  the  risk  of  clinically  relevant  and  dangerous
hemorrhages [18].
Vasorelaxative  properties:  Ginkgo  biloba  increases
microcirculation by improving the endothelium dependent
vasodilation, as shown by the study conducted by Wu et al.
[19].
In their study, the effect of Ginkgo on distal left anterior
descending  coronary  artery  (LAD)  blood  flow  and
endothelium-dependent  brachial  artery  flow-mediated
dilation (FMD) was tested in healthy elderly adults. Sixty
healthy  elderly  adults  were  randomly  assigned  to  either
Ginkgo biloba extract (GBE) or control groups. LAD blood
flow and brachial artery FMD were measured non-invasively
using high-resolution ultrasound before and after intravenous
administration of GBE or saline. GBE significantly increased
LAD blood flow in maximal diastolic peak velocity (MDPV),
maximal systolic peak velocity (MSPV) and diastolic time
velocity integral (DTVI) compared with the placebo group.
Brachial artery FMD was also significantly increased. A linear
correlation  was  found  between  the  percentage  change  in
MDPV,  MSPV,  or  DTVI  of  LAD  blood  flow  and  the
percentage  change  in  brachial  artery  FMD  following
treatment  with  GBE.  These  data  demonstrate  that  GBE
treatment in healthy elderly adults leads to the increase of
LAD  blood  flow  in  MDPV,  MSPV  and  DTVI,  and  the
increased response might relate to the improved endothelium-
dependent vasodilatory capacity.
Antivasospastic  properties:  In  many  clinical  conditions,
particularly  in  glaucoma,  vasospasms  play  a  crucial  role
[20].
The antivasospastic property of Ginkgo biloba has clearly
been demonstrated by Bayar et al. [21]. The authors of the
study investigated the effects of EGb761 on basilar artery
vasospasm  in  an  experimental  canine  subarachnoid
hemorrhage model. Morphometric analyses were performed,
and serum and cerebrospinal fluid endothelin-l levels were
measured  by  radioimmunoassay.  Comparisons  were  made
between treated and untreated groups. Twenty-four mongrel
dogs were randomly assigned to three groups. The animals in
group 1 (n=8) were not subjected to subarachnoid hemorrhage
and  received  no  treatment.  In  this  group,  serum  and
cerebrospinal fluid endothelin-l levels were measured daily
for 8 days. On day 9, the animals were killed and their basilar
arteries were excised for histopathological examination. In
group 2 (n=8), subarachnoid hemorrhage was produced using
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saline were administered for the next 8 days. Assessments of
endothelin-l levels and the basilar arteries were performed as
described  for  group  1.  In  group  3  (n=8),  subarachnoid
hemorrhage was produced using autologous arterial blood,
and daily intravenous boluses of EGb761 were administered
for 8 days. Endothelin-1 levels and the basilar arteries were
assessed as described above. The groups' serum endothelin-1,
cerebrospinal  fluid  endothelin-1,  and  histopathological
findings  were  compared.  In  group  3,  the  serum  and
cerebrospinal  fluid  endothelin-1  levels  followed  the  same
pattern observed in group 2; however, the arteries showed
significantly less vasospasm than that observed in group 2.
The results clearly show that intravenous boluses of EGb761
decreases morphologic vasospasm in the dog basilar artery.
This finding is of great interest, as endothelin is increased in
glaucoma patients, particularly in patients with normal tension
glaucoma.
GINGKO BILOBA AND GLAUCOMA
Pathophysiology  of  glaucoma:  Ginkgo  biloba  positively
influences oxidative stress and disturbed vascular circulation.
Both  reduced  microcirculation  and  oxidative  stress  are
involved in the pathogenesis of glaucoma. Therefore, already
from  a  theoretical  point  of  view,  the  pharmacological
properties of Ginkgo can be expected to be beneficial for eye
as well. Before focusing on the potential benefit of Ginkgo for
glaucoma in the following sections, the pathomechanisms
involved in the ocular disease induced by oxidative stress and/
or disturbed microcirculation are summarized below.
When discussing glaucoma, there is a need to clearly
separate mechanisms leading to an increase in intraocular
pressure (IOP) and mechanisms that lead to glaucomatous
damage  also  known  as  glaucomatous  optic  neuropathy
(GON).
There are different aspects to the pathomechanisms in
both  conditions.  Oxidative  stress  is  involved  in  the
pathogenesis of IOP, whereas for GON, factors associated
with disturbed vascular regulation play a major role. Both
aspects may potentially be influenced by a Ginkgo therapy
and are discussed in more detail below.
Intraocular pressure (IOP)—Oxidative stress has been
implicated to be a cause of increased intraocular pressure by
triggering trabecular meshwork (TM) degeneration and thus
contributing to alterations in the aqueous outflow pathway
[22,23]. The human TM is composed of collagen lamellae
lined by endothelial cells. The space between the collagen
beams of the TM is filled with extracellular matrix, composed
mostly of glycoproteins and proteoglycans, where the aqueous
humor filters through [24,25]. The TM is in constant contact
with the aqueous humor from which ROS may be generated
through  light  catalyzed  reactions,  metabolic  pathways  or
inflammation [22,24,26,27]. Disturbance of the TM cell status
by an insult such as oxidative stress, may lead to cellular loss
and an overexpression or alteration in the structures of various
glycoproteins in the extracellular matrix [25,28,29], which
interfere with the TM function, and lead to impaired aqueous
humor outflow and thereby an increase in IOP.
The pathogenic role of oxidative stress in increasing IOP
by reducing aqueous outflow facility, is supported by various
experimental studies performed in vitro and in vivo. In vitro
treatment of human TM cells with hydrogen peroxide alters
cellular adhesion and integrity [25]. In an animal study of calf,
perfusion of TM cells with peroxide has shown to reduce
aqueous humor drainage from the anterior chamber of the
calf's eye [30]. In humans, oxidative DNA damage has been
reported to be significantly higher in the TM cells of glaucoma
patients than in those of age-matched controls [31]. Further
studies  demonstrate  abundant  oxidative  nucleotide
modification  (8-OH-dG)  levels  in  human  TM  to  be
significantly correlated to the increase in IOP and to visual
field damage [30,32]. Further evidence suggests that patients
with POAG exert mitochondrial abnormalities implicating
that  mitochondrial  dysfunction  is  most  probably  a
consequence of oxidative stress [33]. Free radicals, contained
in the aqueous humor contribute to pathogenic alterations in
the  TM  [34].  Findings  show  resistance  to  the  outflow  of
aqueous  humor  of  calf,  as  a  result  of  TM  cytoskeletal
rearrangements and cellular loss, in the presence of increased
levels  of  hydrogen  peroxide  [30].  The  damage  done  by
prooxidants  to  the  aqueous  humor  outflow  system  may
explain  why  radiologists  more  often  suffer  from  ocular
hypertension  [35].  At  the  molecular  level,  human  TM
endothelium has been reported to be an enriched site of both
endothelin and nitric oxide (NO) synthesis. Nitric oxide can
interact  with  oxygen  or  metals  such  as  copper  or  iron  to
modulate outflow resistance of the TM [36].
Moreover, findings suggest activity of the antioxidant
defense in the aqueous outflow system: glaucoma patients
display a significant depletion of total antioxidant potential in
their aqueous humor [37] a decrease in plasmatic glutathione
levels  [38],  and  an  increase  in  serum  antibodies  against
glutathione-S-  transferase  [39].  The  expression  of
endothelial–leukocyte adhesion molecule (ELAM-1), which
provides protection against oxidative stress, is increased in the
TM of glaucoma patients [40]. Another notable antioxidant,
namely glutathione, is also found in high concentrations in
both aqueous humor and in the TM of mammals [30,41]. In
addition, the heat shock protein, alpha-B crystalline, which
protects from oxidative damage, is overly expressed in TM
cells of both human and monkey eyes stressed by heat [42].
All these changes can be primary or secondary of nature.
Glaucomatous  optic  neuropathy  (GON)—Beside
increased  IOP,  vascular  damage  and  hypoxia  are  often
associated  with  glaucoma.  Interestingly,  however,
arteriosclerosis and its risk factors are only weakly associated
with GON. The factors related to disturbed autoregulation, in
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play in GON a more important role. These factors are best
observed in normal tension glaucoma patients, as described
by Kaiser et al. [43]. An insufficient autoregulation increases
the risk for an unstable ocular perfusion, leading to an unstable
oxygen  supply.  This  unstable  oxygen  supply  generates
oxidative stress. As a consequence of oxidative stress, the
concentration of superoxide (O2-) within the axons of the optic
nerve  head  increases.  The  activation  of  the  neighboring
astrocytes by mechanical or by ischemic stress induces the
production of nitric oxide (NO) in excess. NO diffuses into
the  axons  and  fuses  with  superoxide.  The  resulting
peroxynitrate (ONOO-) diffuses within the axons toward the
retina and the lateral geniculate nucleus and induces apoptosis
[44].
The activation of the astrocytes has been shown to be
another sign of oxidative stress in the optic nerve of glaucoma
patients [45].
These data indicates that beside IOP, disturbed regulation
of microcirculation and oxidative stress are major risk factors
leading to GON. Both aspects can be influenced by Ginkgo.
Effect  of  Ginkgo  biloba  on  glaucomatous  optic
neuropathy—Normal-tension glaucoma, is characterized by
progressive optic nerve damage and visual field loss with a
statistically  normal  intraocular  pressure.  Normal-tension
glaucoma  is  thought  to  be  related,  at  least  in  part,  to
dysregulated blood flow of the optic nerve [46].
There are animal models for high tension glaucoma but
neither for normal tension glaucoma nor for high tension
glaucoma that progresses despite normalized IOP.
Although robust animal models are lacking, Ginkgo is
used by glaucoma specialists for treatment of patients with
normal tension glaucoma and for patients with a glaucoma
that progresses despite IOP lowering treatment. This use is
motivated by the fact, that on the one hand, there are currently
no other therapeutic options for these cases and on the other
hand, the pharmacological profile of Ginkgo exactly fits to the
pathophysiology of these special conditions.
In this context, it is however necessary to emphasize that
a classical separation between pre-clinical and clinical data
are difficult or impossible. While classical animal models with
increased IOP do exist [47,48], there are no animal models
available  for  the  following  two  conditions:  a)  for  normal
tension glaucoma and b) for glaucoma that progresses despite
a normalized IOP. However, these conditions are exactly the
ones in which microcirculation and oxidative stress are of
particular relevance and therefore potentially treatable with
Ginkgo.
Pre-clinical data in a traditional sense are not directly
available  to  assess  the  beneficial  effect  of  Ginkgo  for  a)
normal tension glaucoma and b) glaucoma that progresses
despite a normalized IOP. It is, however, possible to make
meaningful extrapolations from other pathological conditions
(although they may not always be related with the ocular
organ).
As summarized by Tezel G, oxidative stress is clearly is
involved in the pathogenesis of glaucoma [49].
Reactive  oxygen  species  (ROS)  are  generated  as  by-
products  of  cellular  metabolism,  primarily  in  the
mitochondria. Although ROS are essential participants in cell
signaling  and  regulation,  when  their  cellular  production
overwhelms  the  intrinsic  antioxidant  capacity,  damage  to
cellular macromolecules such as DNA, proteins, and lipids
ensues.  Such  state  of  “oxidative  stress”  is  thought  to
contribute to the pathogenesis of several neurodegenerative
diseases.  Growing  evidence  supports  the  involvement  of
oxidative stress as a common component of glaucomatous
neurodegeneration in different subcellular compartments of
retinal ganglion cells (RGCs) [50-52]. Besides the evidence
of direct cytotoxic consequences leading to RGC death, it also
seems highly possible that ROS are involved in signaling RGC
death.  In  this  signaling  pathway,  ROS  act  as  a  second
messenger  and/or  modulates  protein  function  by  redox
modifications  of  downstream  effectors  through  enzymatic
oxidation  of  specific  amino  acid  residues  [53].  Different
studies  provide  cumulating  evidence,  which  supports  the
association  of  ROS  with  different  aspects  of  the
neurodegenerative  process  [54-56].  Oxidative  protein
modifications  during  glaucomatous  neurodegeneration
increase neuronal susceptibility to damage and also lead to
glial dysfunction [57]. Oxidative stress-induced dysfunction
of glial cells may contribute to spreading neuronal damage by
secondary degeneration [58]. Oxidative stress also promotes
the  accumulation  of  advanced  glycation  and  products  in
glaucomatous tissues [59]. In addition, oxidative stress takes
part  in  the  activation  of  immune  response  during
glaucomatous neurodegeneration [60], as ROS stimulate the
antigen presenting ability of glial cells and also function as
co-stimulatory molecules during antigen presentation.
On one hand, there is clear evidence that oxidative stress
plays a role in the pathogenesis of GON and on the other hand,
there is enough evidence with regard to the antioxidative
property of Ginkgo biloba.
The  potential  value  of  antioxidative  treatment  in
glaucoma was recently summarized by Mozaffarieh et al.
[61]. The authors consider antioxidative treatment meaningful
in glaucoma even though the clinical evidence is sparse.
Several peer-reviewed data support the involvement of
mitochondria dysfunction in the pathogenesis of glaucoma
[60,62,63].
Evidence regarding the improvement of mitochondrial
function  with  Ginkgo  exists.  EGb761  given  shortly  after
initiating  mitochondrial  damage  by  sodium  nitroprusside
(nitric oxide donor) improved the mitochondrial membrane
potential of PC12 cells significantly and dose dependently.
Under these conditions, EGb761 also reversed the decrease in
ATP production. These findings clearly show stabilization
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sensitive property of EGb761 at therapeutically relevant doses
[12]. In an in vitro study EGb761 alleviated mitochondrial
functions (ATP levels and mitochondrial membrane potential)
at concentrations as low as 0.01 mg/ml 14].
Disturbed microcirculation plays a crucial role in the
pathogenesis  of  glaucomatous  damage  [10].  An  unstable
ocular perfusion, either due to IOP fluctuation or a disturbed
autoregulation  (due  to  primary  vascular  dysregulation
syndrome), leads to a mild reperfusion injury. The fusion of
superoxide (O2
.-) anion (produced in the mitochondria of the
axons)  with  the  nitric  oxide  (NO;  diffusing  from  the
astrocytes)  results  in  the  production  of  peroxynitrite
(ONOO–). It is possible that the diffusion of endothelin and
metalloproteinases to the surrounding of the optic nerve head
leads  to  a  local  vasoconstriction.  This  vasoconstriction
increases the risk for venous occlusion and weakens the blood-
brain barrier, which in extreme situations results in splinter
hemorrhages.  The  involvement  of  primary  vascular
dysregulation  in  the  pathogenesis  of  glaucomatous  optic
neuropathy may explain why women, as well as Japanese,
suffer more often from normal-tension glaucoma.
It is known that ginkgo improves microcirculation in the
brain and it may therefore be assumed that ginkgo exerts a
similar effect in the eye. Zhang et al. [64] investigated the
therapeutic effect of EGb761 on hypertension and its possible
mechanisms in the view of cerebral microcirculation in twenty
normotensive  rats  and  24  spontaneously  hypertensive  rat
(SHR)  rats.  They  suggested  that  EGb761  had  therapeutic
effect on SHR rats by increasing blood perfusion, regulating
vasomotion  function,  opening  efficiently  capillaries  and
releasing  the  peripheral  resistance.  It  was  concluded  that
EGb761 could be used to regulate hypertension and to protect
the cerebral microcirculatory function.
Although the investigation of Zhang et al. was done at the
cerebral level, it may be assumed that similar conclusion may
be drawn for the eye.
A mild but repeated reperfusion injury (either due to IOP
fluctuating  on  a  level  that  momentarily  exceeds
autoregulation capacity or due to disturbed autoregulation)
leads to the oxidative stress and thereby to glaucomatous
damage on the long run [65].
Ginkgo  reduces  ischemia/reperfusion  injury  in  the
ischemic/reperfused  diabetic  rat  retina.  This  has  been
demonstrated  by  the  free  radical  scavenging  property  of
Ginkgo [66]. Hao et al. [67] studied the role of Ginkgo in the
hearts  of  rats  with  from  ischemia-reperfusion.  They
investigated  the  function  of  isolated  hearts  subjected  to
ischemia-reperfusion (IR) with or without Ginkgolide B (GB)
pretreatment. They found that GB exposure improved the
function of left ventricle from IR injury and decreased infarct
size and the release of lactate dehydrogenase (LDH). The
results of the study showed that GB could partly prevent IR
injury in rat heart.
Based on the results observed in rat diabetic retina and
ischemia-reperfusion in rat heart, it can be assumed that a
Figure 2. Surviving retinal ganglion cells distribution in the retina in a rat model of chronic glaucoma. Three groups of animals: A: control,
B: EGb761-treated for 5 months, and C: vehicle-treated. A difference between surviving retinal ganglion cells distribution in eyes with elevated
IOP that were treated with EGb 761 and vehicle. Reproduced with permission from Hirooka et al. [71].
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395similar beneficial effect of ginkgo occurs in the optic nerve
head of glaucoma patients, as these patients also suffer from
ischemia-reperfusion injury.
Optic disc hemorrhages are associated with a higher risk
for  progression.  Normal  tension  glaucoma  is  particularly
affected by these hemorrhages [68].
However the frequency of these hemorrhages cannot be
reduced  by  IOP  lowering  treatment  [69]  and  there  is  no
treatment available at present to reduce this risk factor. It is
known,  however,  that  Ginkgo  (EGb761),  can  prevent
vasospasm in subarachnoidal hemorrhages [70]. Therefore it
can be assumed that Ginkgo has also a beneficial effect in
glaucoma patients with optic disc hemorrhages.
As mentioned above, animal models for normal tension
glaucoma – or for glaucoma progressing despite a normalized
IOP – do not exist. Nevertheless, even in classical high tension
glaucoma animal models, ginkgo has been shown to reduce
glaucomatous damage [71].
High  tension  glaucoma—Unlike  for  normal  tension
glaucoma, an accepted therapy for high tension glaucoma
exists, namely the IOP lowering treatment. In addition, in the
case  of  high  tension  glaucoma,  factors  like  disturbed
microcirculation  or  oxidative  stress  seem  to  play  a  less
important role than in normal tension glaucoma. The fact that
ginkgo had a clearly beneficial effect even in animals with
high tension glaucoma is therefore even more remarkable: the
effect of Ginkgo biloba extract against neurotoxicity of retinal
ganglion  cells  was  investigated  in  rats  with  chronic
moderately  elevated  intraocular  pressure  (IOP)  [71].
Unilateral chronic moderately elevated IOP was produced in
rats  by  cautery  of  three  episcleral  vessels.  Secondary
degeneration  was  measured  with  and  without  EGb761
treatment for 5 months. After 5 months, the retinal ganglion
cells loss between the EGb761 treated group and the control
group (no EGb761 treatment) was compared. The authors of
the  study  concluded  that  pre-treatment  and  early  post-
treatment with EGb761 is an effective neuroprotectant in a rat
model of chronic glaucoma (Figure 2 and Figure 3).
Overall conclusion from the experimental data for
Ginkgo  biloba  and  glaucoma—Based  on  the  present
knowledge  of  the  pathogenesis  of  glaucomatous  damage,
Ginkgo interferes positively on different steps involved in the
pathogenesis  of  glaucomatous  damage  (oxidative  stress,
microcirculation,  mitochondrial  function  etc).  However
experimental  models  for  normal  tension  glaucoma  or  for
glaucomatous progression despite normal IOP do not exist.
Therefore, the conclusions are based on extrapolation of other
studies. And these extrapolations reveal a clear positive effect
of Ginkgo.
But even in high tension glaucoma, where IOP plays a
major role (whereas factors such as impaired microcirculation
and oxidative stress are less relevant) and where an accepted
therapy (namely the IOP lowering therapy) is available, the
effect of ginkgo was highly significantly positive.
While all publications are indirectly in favor for Ginkgo,
no single publication contradicts the positive effect of Ginkgo.
Clinical data: Glaucoma is a chronic progressive disease, in
which  the  damage  develops  over  decades.  Double  blind
controlled  long-term  studies  are  needed  to  definitively
evaluate the value of a glaucomatous drug. However such
controlled studies are money and time consuming. Therefore,
very few controlled studies have been performed in glaucoma
for any type of glaucoma treatment. To simplify the evaluation
of the efficacy of so called glaucoma drugs, IOP is normally
used as a surrogate in clinical trials. It is known from large
scale  studies,  that  IOP  lowering  treatment  is  particularly
helpful  for  high  tension  glaucoma.  To  some  extent,  IOP
lowering  treatment  is  also  helpful  for  normal  tension
glaucoma. However these studies have also demonstrated that
a large part of patients (particularly in the group of normal
Figure 3. The effect of gingko extract (EGb76) on retinal ganglion
cells of rats. A: Retinal ganglion cells density in retinas with chronic,
moderately elevated IOP. Retinal ganglion cells (RGC) were counted
in the peripheral retina, approximately 4.0 mm from the optic disc.
The  graph  depicts  the  mean±standard  deviation  of  five  animals
treated  with  vehicle.  A  significant  difference  between  retinal
ganglion cell densities in eyes with elevated IOP that were treated
with EGb 761 and vehicle was evident (p=0.0007). Four groups of
animals:  1)  Control  without  treated,  2)  eyes  with  elevated  IOP
without treated (Operated, none), 3) Control, treated with EGb 761,
4) eyes with elevated IOP, treated ith EGb 761 (Operated, EGb761).
B: Retinal ganglion cells lost at 5 months in rat eyes with chronic,
moderately elevated IOP. Two groups: 1) Not treated, 2) Treated with
EGB761. Reproduced with permission from Hirooka et al. [71].
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396tension glaucoma patients) progress despite a normalized IOP
[46]. The progression of glaucoma often occurs even if a very
low  IOP  has  been  reached  by  IOP  lowering  treatment.
Therefore, there is an urgent need for an additional – non IOP
lowering – glaucoma treatment.
The only such treatment that gained more or less general
acceptance – even without definitive scientific proof – is a
treatment with Ginkgo [72,73]. Glaucomatologists have been
using Ginkgo for their patients successfully since many years.
From  their  point  of  view,  Ginkgo  is  indicated  a)  in
patients with normal tension glaucoma and b) in glaucoma
patients  that  progress  despite  a  normalized  IOP.  This
indication  is  based  on  the  fact  that  a)  beside  IOP,  the
pathogenic  factors  involved  in  the  disease  are  disturbed
microcirculation and oxidative stress, both conditions which
can  be  influenced  by  Ginkgo.  b)  there  are  currently  no
alternative treatment for such cases. c) a significant positive
effect in favor of Ginkgo was observed both in experimental
glaucoma animals and in glaucoma patients.
Pathomechanisms  involved  in  glaucoma—In
glaucoma  patients,  ocular  blood  flow  is  reduced  both  in
patients with normal tension glaucoma and in patients that
progress despite a normalized IOP. Kaiser et al. [43] measured
hemodynamic parameters in the ophthalmic artery, central
retinal artery, central retinal vein, and lateral and medial short
posterior ciliary arteries by color Doppler imaging in 237
patients  with  primary  open-angle  glaucoma  and  124  age-
matched  normal  control  subjects.  All  patients  showed  a
significant  decrease  in  end-diastolic  velocities  and  a
significant  increase  in  resistivity  index  in  all  arteries
measured. Their data showed that hemodynamic parameters
in  the  extraocular  vessels  are  altered  in  patients  with
glaucoma.
Several  studies  have  demonstrated  that  blood  flow
reduction has a negative predicting power for progression
[74,75]. In a retrospective observational case studies, Satilmis
et al. [76] evaluated the correlation between progression rate
of glaucomatous damage and retrobulbar blood flow in an
institutional setting. Twenty open-angle glaucoma patients
with at least five visual field examinations and progressive
damage in at least one eye were included in the study. As an
indicator of progression rate of visual field damage, the angle
to a horizontal line of the slope of the regression line of the
visual field index mean defect over time was calculated for
one  randomly  selected  eye  per  patient.  The  association
between this angle and intraocular pressure, as well as retro
bulbar color Doppler imaging measurements, were analyzed
by a multiple linear regression analysis in a stepwise forward
approach.  A  faster  rate  in  progression  of  glaucomatous
damage was observed by a lower baseline end diastolic blood
flow velocity in the central retinal artery and a higher baseline
intraocular pressure. The rate of progression was not related
to the extent of preexisting visual field damage and IOP. The
authors of the study concluded that a significant correlation
exists between the progression rate of glaucomatous visual
field damage and retrobulbar hemodynamic variables.
Effects  of  Ginkgo  on  ocular  microcirculation—
Ginkgo  improves  ocular  blood  flow.  Chung  et  al.  [77]
evaluated  a  possible  therapeutic  effect  of  Ginkgo  biloba
extract (GBE) on glaucoma patients who may benefit from
improvements  in  ocular  blood  flow.  A  Phase  I  placebo-
controlled  crossover  trial  in  11  healthy  volunteers  was
performed. Patients were treated with either GBE (40 mg) or
placebo three times daily orally, for 2 days. Color Doppler
imaging was used to measure ocular blood flow before and
after  treatment.  There  was  a  two  week  washout  period
between GBE and placebo treatment. Ginkgo biloba extract
significantly increased end diastolic velocity (EDV) in the
ophthalmic artery (OA), with no change seen in placebo. No
side effects related to GBE were found. GBE did not alter
arterial blood pressure, heart rate, or IOP. The authors of the
study concluded that GBE significantly increased EDV in the
OA. According to them, the beneficial properties of GBE on
ocular blood flow deserve further investigation as a potential
treatment of glaucomatous optic neuropathy (as well as other
ischemic ocular diseases).
Although the experimental data have been performed
with  healthy  subjects,  these  data  support  the  finding  that
Ginkgo may be beneficial for glaucomatous disease where
ocular microcirculation is impaired.
Novel  strategies  for  Glaucoma  treatment—While
classic glaucoma treatment focuses on IOP reduction, open
question remains, as cases exist for which a reduction of IOP
does not stop the progression of the disease. Besides, a better
knowledge of the pathogenesis of the disease has opened up
new  therapeutical  approaches.  The  different  therapeutic
options, which are targeted toward factors other than. The
non-IOP lowering drugs described in the review are targeted
at  different  levels  of  the  pathophysiology  involved  in
glaucomatous optic neuropathy, such as: inhibition of the
activation of astrocytes, inhibition of nitric-oxide synthase 2,
improvement  of  vascular  regulation,  counteract  oxidative
stress, inhibition of matrix metalloproteinase, upregulation of
heat shock protein, neuroprotection [78].
Positive preclinical data have been obtained with drugs
inhibiting the activation of astrocytes, nitric-oxide synthase 2
inhibitor,  matrix  metalloproteinase-9  inhibitor,  drugs  with
neuroprotective properties and with the upregulation of heat
shock  proteins.  However,  data  supporting  their  potential
effectiveness in glaucoma treatment in human are not yet
available.
In small open cohort studies, the improvement of ocular
blood  flow  with  carbonic  anhydrase  inhibitors,  like
acetazolamide,  has  shown  to  improve  visual  fields  in
glaucoma patients [79,80]. Similar results were also observed
with  calcium  channel  blockers  in  patients  with  vascular
dysregulation [81]. Besides, in a placebo-controlled, double-
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reversibility of visual field damage in patient with normal
tension glaucoma.
As the field of vision is affected at the early stages of
glaucomatous disease, the visual fields are the most important
parameter to quantify glaucomatous damage.
In a placebo controlled double blind study, treatment with
ginkgo has also induced some reversibility of visual field
damage in normal tension glaucoma [82].
The authors of the study evaluated the effect of Ginkgo
biloba extract (GBE) on preexisting visual field damage in
patients with normal tension glaucoma (NTG) with the help
of  a  prospective,  randomized,  placebo-controlled,  double-
masked crossover trial. Twenty-seven patients with bilateral
visual field damage resulting from NTG participated. Patients
received 40 mg GBE, administered orally, three times daily
for 4 weeks, followed by a wash-out period of 8 weeks, then
4 weeks of placebo treatment. Other patients underwent the
same regimen, but took the placebo first and the GBE last.
Visual field tests, performed at baseline and at the end of each
phase of the study, were evaluated for changes. Changes in
visual field and any ocular or systemic complications were the
main outcome measures. After GBE treatment, a significant
improvement in visual fields indices was recorded. Neither
ocular nor systemic side effects were observed for the duration
of  the  trial.  It  can  be  concluded  from  this  study  that  the
administration of Ginkgo biloba extract improves preexisting
visual field damage in some patients with NTG (Figure 4).
Beside  increased  IOP,  disturbed  microcirculation  and
oxidative stress are involved in the pathogenesis of glaucoma.
Ginkgo has clearly been proven to improve microcirculation
and the antioxidative capacity. Moreover, the main damage in
glaucoma occurs in the mitochondria and Ginkgo clearly has
a  stabilizing  effect  on  the  mitochondria.  Optic  disc
hemorrhages  often  occur  in  glaucoma  patients  and  are
associated with reduced prognosis. By extrapolating the data
obtained in the brain, it can be assumed that ginkgo has also
a beneficial effect in optic disc hemorrhages. Preclinical data
have shown the protective effect of ginkgo on the retinal
ganglion  cells  in  experimental  glaucomatous  animals.
Moreover, the potential beneficial value of Ginkgo has been
described in one clinical double-blind study, in which Ginkgo
has even induced some reversibility of glaucomatous visual
field damage. With the exception of a single study which
investigated  the  hemodynamic  parameters  after  a  single
administration  of  Ginkgo  biloba,  no  other  study  revealed
negative results.
SAFETY
Adverse reactions under Ginkgo biloba treatment: According
to published studies and reports, the use of Ginkgo seems safe
and well tolerated. Birks and Grimley cited in their meta-
analysis that there were no differences between Ginkgo biloba
and placebo in the proportion of participants experiencing any
adverse event. The studies selected for this meta-analysis were
administrating Ginkgo extract treatment up to six months.
These data have been confirmed when standardized Ginkgo
biloba was used in standard doses in clinical trials lasting from
one up to six years [83-85].
In rare cases, mild gastrointestinal complaints, headache,
and allergic skin reactions have been reported [86]. There are
several published case reports linking Ginkgo to episodes of
minor to severe bleeding. However, not all case reports clearly
establish Ginkgo as the cause of bleeding. In most cases, other
bleeding risk factors such as intake of other medications, old
age,  liver  cirrhosis  or  recent  surgery  were  also  present.
Bleeding occurred after several weeks or months of taking
Ginkgo biloba [87].
To determine the effect of Ginkgo extract on coagulation
parameters, Kohler et al. [88] assessed in a crossover study
with  fifty  healthy  volunteers  the  effect  on  bleeding  time,
coagulation parameters, or platelet activation and found no
effect. Another placebo-controlled study evaluated the effects
of Ginkgo biloba on homeostasis, coagulation and fibrinolysis
when Gingko biloba extract were administered for two weeks.
This study did not reveal any alteration of platelet function or
coagulation [89]. Besides, large-scale clinical trials evaluating
Figure 4. Improvement in preexisting visual field damage in patients
with normal tension glaucoma after treatment with GBE. Patients are
divided in two groups according to sequences of treatment. Group
A:  sequence  of  treatment:  GBE-  wash  out-  placebo.  Group  B:
sequence of treatment: placebo-washout-GBE. GBE=Gingko biloba.
Reproduced with permission from Quaranta et al. [82].
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that the incidence of bleeding in patients taking Ginkgo is not
significantly higher than in those taking placebo [90,91].
Interaction potential during Ginkgo biloba treatment: The
risk of spontaneous bleeding may be increased when Ginkgo
biloba  extract  is  combined  with  nonsteroidal
antiinflammatory drugs (NSAIDs) and anticoagulants such as
heparin or warfarin [92]. In a recent randomized double-blind,
placebo-controlled clinical trial, the effect of a co-medication
of acetylsalicylic acid (ASA) and Ginkgo extract on platelet
aggregation, bleeding time and coagulation parameters has
been investigated [93]. ASA and the combination of ASA and
Ginkgo  biloba  exerted  similar  effects  on  all  coagulation
parameters  measured,  including  bleeding  time  and  PAF
induced  platelet  aggregation.  Both  treatments  were  well
tolerated, and both number and nature of adverse events in the
two  groups  were  similar.  These  findings  suggest  that  co-
administration of ASA and Ginkgo biloba does not constitute
a safety risk. According to the authors, this finding also applies
for an elderly patient population undergoing treatment with
Ginkgo biloba.
The potential interaction of a standardized Ginkgo extract
with warfarin was tested in a placebo-controlled, crossover
study  involving  24  patients  under  a  long-term  warfarin
treatment [94]. After administration of Ginkgo biloba, the
mean dose of warfarin to maintain the target range for INR of
2.0–4.0 did not have to be changed during either treatment
period.  A  population  pharmacokinetic-pharmacodynamic
modeling approach resulted in similar findings with regard to
the  potential  of  interaction  during  a  co-medication  with
Ginkgo and warfarin [95].
In summary, although there were reports about individual
cases  of  bleeding  (whose  direct  relationship  with  Ginkgo
biloba could not be established and which occurred mainly
with  high-risk  patients),  Ginkgo  biloba  appears  to  be
predominantly safe in the long term use with no excess side
effects compared with placebo.
CONCLUSION
The  classical  treatment  of  glaucoma  is  and  remains  IOP
reduction.  However  in  normal  tension  glaucoma,  the
glaucomatous  disease  progresses  despite  a  normal  or
normalized IOP. As the pharmacological properties of Ginkgo
specifically  target  the  factors  involved  in  glaucomatous
disease (disturbed ocular microcirculation, oxidative stress,
impairment of mitochondrial function in the retinal ganglion
cells), it can be assumed that Ginkgo could theoretically be
beneficial for glaucoma.
Some  authors  did  not  find  any  association  between
Ginkgo biloba extract use and glaucoma or mentioned that
little is known on the long-term impact of medication having
an effect on ocular blood flow. However the date based on a)
the pharmacological properties of ginkgo, b) in vitro-studies,
c) animal studies and d) clinical studies provide cumulating
evidence of the beneficial effect of Ginkgo for the above
mentioned condition.
Ginkgo would probably be beneficial for all glaucoma
patients. However the use of ginkgo can be recommended as
an adjuvant therapy only for normal tension glaucoma patients
and for high tension glaucoma patients progressing despite a
normalized  IOP.  Such  a  limitation  is  economically
meaningful  and  medically  possible,  as  for  these  two
conditions, there are no other therapeutic alternative so far
(beside the IOP- lowering treatment).
Therefore, based on the current data set and the favorable
safety  profile  of  standardized  Ginkgo  biloba  extract,  the
administration of a Ginkgo treatment could be considered in
cases  where  glaucoma  progresses  despite  a  normal  or
normalized IOP.
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